October 14, 2026 update: ELPIS II missed. On Sep 16, 2026 Longeveron reported that the Phase 2b ELPIS II trial in 40 infants with HLHS did not meet its primary endpoint: the change in right ventricular ejection fraction at 12 months differed by −0.7 points between arms (95% CI −7.3 to 5.9; p=0.8336). An exploratory composite of mortality and hospitalization was also not significant. Exploratory as-treated numbers leaned the right way (0 vs. 1 death at 12 months; 12 vs. 19 MACE), but none were statistically significant. Safety was consistent with prior trials. The company says it will analyze the full dataset and discuss next steps with FDA. It has also launched a review of "all options to maximize shareholder value", intends to hire an investment bank, and is cutting costs (Longeveron, Sep 16, 2026). Before the readout, Longeveron did a 1-for-10 reverse split (effective Aug 26, 2026) and regained Nasdaq bid-price compliance (8-K, Sep 14, 2026). Cash was $10.1M at June 30, 2026, with runway guided only into Q4 2026 (Q2 2026 results). The stock was about $1.72 intraday on Oct 14, post-split.
The Thesis in Brief
We put Longeveron on this list in July as a single binary bet on the ELPIS II readout in Hypoplastic Left Heart Syndrome (HLHS). That bet resolved badly. The trial missed its primary endpoint (p=0.8336), and FDA had already told the company RVEF alone would not be enough for approval (Longeveron, Sep 16, 2026).
What is left is a company running a strategic review with about $10.1M in cash at June 30 and runway guided only into Q4 2026. It still has laromestrocel programs in Alzheimer's (RMAT and Fast Track), aging-related frailty (Phase 2b published in Cell Stem Cell, XPRIZE Healthspan finalist) and pediatric dilated cardiomyopathy (Phase 2 targeted for 2027). Management says it will pursue funding for frailty and longevity. A financing, partnership, sale or wind-down are all possible outcomes, and further dilution is likely.
The Science: What Lomecel-B Actually Is
Longeveron is a clinical-stage company built around one platform product. That product is laromestrocel, marketed under the brand name Lomecel-B — an allogeneic medicinal signaling cell / mesenchymal stem cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Because it is allogeneic ("off-the-shelf," donor-derived rather than patient-derived), a single donor source can, in principle, supply many patients.
The therapy is described as having pro-vascular, pro-regenerative, anti-inflammatory and tissue-repair properties. Rather than targeting a single molecular pathway, MSC therapies are understood to act through a broad set of signaling effects on surrounding tissue. Longeveron applies this same single asset across every indication in its pipeline — a structure that is capital-efficient but also concentrates risk, since setbacks or successes with the platform tend to read across programs.
One asset, several indications: capital-efficient by design — and, by the same design, unusually exposed to a single data outcome.
Pipeline: One Asset, Several Indications
1. Hypoplastic Left Heart Syndrome (HLHS) — lead program
HLHS is a rare, life-threatening congenital heart defect in which the left side of the heart is critically underdeveloped. It was Longeveron's lead indication. ELPIS II (Phase 2b, n=40) missed its primary RVEF endpoint on September 16, 2026 (p=0.8336); exploratory clinical outcomes were numerically favorable but not statistically significant, and the company plans to discuss the data with FDA (Longeveron, Sep 16, 2026). The program carries Orphan Drug, Fast Track and Rare Pediatric Disease designations.
2. Alzheimer's Disease (mild AD)
Longeveron has completed a Phase 2a study of Lomecel-B in mild Alzheimer's disease, with a Phase 2/3 pathway now in planning. To be precise about the designations: the RMAT (Regenerative Medicine Advanced Therapy) designation sits on the Alzheimer's program — not on HLHS — together with Fast Track. The Phase 2a Alzheimer's data was published in Nature Medicine in March 2025, and data presented at AAIC 2026 indicated reduced neuroinflammation in Alzheimer's patients.
3. Pediatric Dilated Cardiomyopathy (PDCM)
A Phase 2 program in pediatric dilated cardiomyopathy has an IND that became effective in July 2025, with trial initiation targeted for 2027.
4. Aging-Related Frailty
The company has completed a Phase 2b in aging-related frailty. This is an older, deprioritized program relative to the cardiac and neurology efforts now driving the story.
Catalysts on the Horizon
Regulatory Standing
- HLHS program: Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the U.S. FDA.
- Alzheimer's program: RMAT (Regenerative Medicine Advanced Therapy) designation plus Fast Track — note the RMAT is on Alzheimer's, not HLHS.
- EMA Small/Medium-sized Enterprise (SME) status granted in June 2026 — supporting a potential European pathway.
- A "constructive" Type C FDA meeting was held in late March 2026 ahead of the ELPIS II readout, and in May 2026 an independent data monitoring committee (IDMC) recommended completing ELPIS II as designed, citing no new safety concerns.
Financials & Structure
Cash and cash equivalents were $10.1M at June 30, 2026, and Q2 net loss was $6.1M; management guided runway into Q4 2026 (Q2 2026 results). After the ELPIS II miss the company began cost containment and a review of strategic options (Longeveron, Sep 16, 2026). Longeveron completed a 1-for-10 reverse split effective August 26, 2026 and regained Nasdaq minimum-bid compliance on September 11 (8-K, Sep 14, 2026). The stock was about $1.72 intraday on October 14, 2026. On a split-adjusted basis that is roughly 70% below the ~$0.62 (≈$6.20 adjusted) we cited on July 14. Further dilutive financing is the base case if the company continues as is.
Bull vs. Bear
▲ What remains
- RMAT- and Fast Track-designated Alzheimer's program; Phase 2a published in Nature Medicine.
- Aging-related frailty Phase 2b published in Cell Stem Cell; XPRIZE Healthspan finalist ($1M Milestone 2 award).
- Safety profile consistent across 644 treated participants, per the company.
- Nasdaq bid-price compliance regained in September 2026.
▼ The Bear Case
- ELPIS II missed its primary endpoint; the lead HLHS program has no clear path to approval.
- $10.1M cash (June 30) with runway only into Q4 2026.
- Strategic review outcome uncertain; may not produce a transaction.
- Further dilution likely; stock down ~70% split-adjusted since July 14.
Frequently Asked Questions
What does Longeveron do?
Longeveron is a Miami-based clinical-stage regenerative-medicine company developing a single allogeneic mesenchymal stem cell (MSC) therapy — laromestrocel, brand name Lomecel-B — across several indications. Its most advanced program was Hypoplastic Left Heart Syndrome (HLHS), where ELPIS II missed its primary endpoint in September 2026, with additional programs in Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty.
What is laromestrocel / Lomecel-B?
Laromestrocel (brand name Lomecel-B) is Longeveron's allogeneic medicinal signaling / mesenchymal stem cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. It is described as having pro-vascular, pro-regenerative, anti-inflammatory and tissue-repair properties, and is the company's single platform product used across all indications.
What happened in the ELPIS II HLHS trial?
Longeveron reported ELPIS II top-line results on September 16, 2026: the trial did not meet its primary endpoint (change in right ventricular ejection fraction at 12 months; p=0.8336). The company plans to discuss the data with FDA and has begun a review of strategic options.
What is a Priority Review Voucher, and why does Rare Pediatric Disease designation matter?
Longeveron's HLHS program carries FDA Rare Pediatric Disease designation. If a therapy with that designation is approved, the sponsor may receive a Priority Review Voucher (PRV) — a transferable voucher usable to expedite another drug's FDA review, or sellable to a third party. PRVs have historically sold for substantial sums, so for a microcap the potential of a PRV can represent meaningful non-dilutive value — though it is contingent on approval, which is not assured.
What are the main risks?
We don't give buy/sell recommendations. Longeveron is a high-risk, single-asset microcap. Its ELPIS II HLHS trial missed its primary endpoint in September 2026, cash was $10.1M at June 30, 2026 with runway guided only into Q4 2026, and the company is reviewing strategic options, so further dilution or a transaction is likely. It completed a 1-for-10 reverse split in August 2026 and regained Nasdaq bid-price compliance in September — including the potential loss of the entire investment. Do your own research (DYOR) and consult a licensed financial professional. See the full disclosure below.